Faculty profile

ANDREW FEIFER

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

ANDREW FEIFER

Researcher

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
8 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Advanced Practice Nurses Breast Cancer Cancer Care Continuum Electronic Patient Reported Outcomes Models Of Care Delivery Patient-Centred Care Prostate Cancer Service Design

Latest papers

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir
Future Oncology · 2026
Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.
European urology · 2026
Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.
BJU international · 2026

All 13 publications

Latest funding

Development, multi-ancestry international validation, algorithmic audit, and prospective silent trial evaluation of PRISM - A globally accessible, patient-oriented artificial intelligence-based model to predict the presence of clinically significant prostate cancer
CIHR · 2023 · Co-investigator
$462,824
Virtualizing survivorship: Implementing a more timely and comprehensive model of follow-up care
CIHR · 2019 · Principal investigator
$1,081,093

All 2 grants and awards

13 publications.

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir

Ong M, Morash C, Hamilton RJ, Gotto GT, Rendon RA, Malone S, Antebi E, Kolinsky MP, Hotte SJ, N. K

Future Oncology2026

DOI: 10.1080/14796694.2026.2665814

Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.

Kwong JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Ringa M, Feifer A, Lajkosz K, Wettstein MS, Chan A, Lee T, Nguyen M, Kassouf W, Black PC, Breau RH, Lodde M, Fairey A, Lattouf JB, Jeldres C, Rendon R, Alimohamed N, Fleshner NE, Diamand R, Gontero P, Sylvester RJ, van Rhijn BWG, Kamat AM, Johnson AEW, Zlotta AR, Kulkarni GS, PROGRxN-BCa Consortium

European urology2026

DOI: 10.1016/j.eururo.2025.09.4145 PMID: 41062388

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.

Pace KJC, Kwong JCC, Randhawa H, Ringa M, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Haile S, Ali A, Wettstein M, Chan A, Perlis N, Lee J, Hamilton R, Fleshner N, Finelli A, Jamal M, Papanikolaou F, Short T, Feifer A, Kulkarni G, Zlotta AR

BJU international2026

DOI: 10.1111/bju.70085 PMID: 41260885

Pre-Implementation Assessment of a Sexual Health eClinic in Canadian Oncology Care

Incze T, Peres D, Guirguis S, Neil-Sztramko SE, Bender J, Elterman D, Alibhai SMH, Finelli A, Bach PV, Belita E

Current Oncology2025

DOI: 10.3390/curroncol32070395

Genetic testing practices among specialist physicians who treat prostate cancer: A Canadian cross-sectional survey

Yip SM, Morash C, Kolinsky MP, Kapoor A, Ong M, Selvarajah S, Nuk J, Compton K, Pouliot F, Lavallée LT

Journal of the Canadian Urological Association20234 citationsOpen Access

DOI: 10.5489/cuaj.8403 PMID: W4385074059

Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort study.

Kwong JCC, Khondker A, Meng E, Taylor N, Kuk C, Perlis N, Kulkarni GS, Hamilton RJ, Fleshner NE, Finelli A, van der Kwast TH, Ali A, Jamal M, Papanikolaou F, Short T, Srigley JR, Colinet V, Peltier A, Diamand R, Lefebvre Y, Mandoorah Q, Sanchez-Salas R, Macek P, Cathelineau X, Eklund M, Johnson AEW, Feifer A, Zlotta AR

The Lancet. Digital health2023

DOI: 10.1016/s2589-7500(23)00067-5 PMID: 37211455

Meningeal metastases in prostate cancer: Institutional series and comprehensive systematic review.

Khondker A, Budiansky D, Kwong JCC, Ali A, Chen YA, Feifer A

Urologic oncology2023Senior author

DOI: 10.1016/j.urolonc.2022.08.004 PMID: 36088245

Explainable artificial intelligence to predict the risk of side-specific extraprostatic extension in pre-prostatectomy patients.

Kwong JCC, Khondker A, Tran C, Evans E, Cozma AI, Javidan A, Ali A, Jamal M, Short T, Papanikolaou F, Srigley JR, Fine B, Feifer A

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2022Senior author

DOI: 10.5489/cuaj.7473 PMID: 35099382

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

Gotto G, Drachenberg DE, Chin J, Casey R, Fradet V, Sabbagh R, Shayegan B, Rendon RA, Danielson B, Camacho F

Journal of the Canadian Urological Association202012 citationsSenior author

DOI: 10.5489/cuaj.6388

Virtual care models for cancer survivorship.

Pham Q, Hearn J, Gao B, Brown I, Hamilton RJ, Berlin A, Cafazzo JA, Feifer A

NPJ digital medicine2020Senior author

DOI: 10.1038/s41746-020-00321-3 PMID: 32923690

Something wrong or missing on this profile? Suggest a correction

ANDREW FEIFER

Research

Latest papers

Latest funding

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir

Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.

Pre-Implementation Assessment of a Sexual Health eClinic in Canadian Oncology Care

Genetic testing practices among specialist physicians who treat prostate cancer: A Canadian cross-sectional survey

Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort study.

Meningeal metastases in prostate cancer: Institutional series and comprehensive systematic review.

Explainable artificial intelligence to predict the risk of side-specific extraprostatic extension in pre-prostatectomy patients.

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

Virtual care models for cancer survivorship.

Development, multi-ancestry international validation, algorithmic audit, and prospective silent trial evaluation of PRISM - A globally accessible, patient-oriented artificial intelligence-based model to predict the presence of clinically significant prostate cancer

Virtualizing survivorship: Implementing a more timely and comprehensive model of follow-up care

Frequent collaborators

Antonio Finelli

Bobby Shayegan

Nathan Perlis

Quynh Pham

Sebastien Hotte

Michael Ong

Dean Elterman

Jeffrey Campbell

Jackie Bender

Gerald Brock

Jennifer Nuk

Ryan Flannigan

Neil Fleshner

Wassim Kassouf

Sarah Neil-Sztramko

Alejandro Berlin

Emily Belita

Girish Kulkarni

Robert Hamilton

Vincent Fradet